Medicus Pharma Ltd (NASDAQ: MDCX) has seen a decline in its stock price by -9.49 in relation to its previous close of 2.95. However, the company has experienced a -2.91% decline in its stock price over the last five trading sessions. proactiveinvestors.com reported 2025-06-09 that Medicus Pharma (NASDAQ:MDCX) said on Monday it has submitted a comprehensive product development plan to the US Food and Drug Administration (FDA) to advance its investigational treatment for external squamous cell carcinoma (SCC) in horses. The plan was submitted under the company’s existing Investigational New Animal Drug file and follows the FDA’s Minor Use in Major Species designation, which Medicus received in December 2024 for its dissolvable Doxorubicin-containing microneedle array (D-MNA).
Is It Worth Investing in Medicus Pharma Ltd (NASDAQ: MDCX) Right Now?
Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MDCX is 2.34M and currently, short sellers hold a 16.16% of that float. On June 12, 2025, MDCX’s average trading volume was 191.28K shares.
MDCX’s Market Performance
MDCX stock saw a decrease of -2.91% in the past week, with a monthly decline of -45.06% and a quarterly a decrease of -18.84%. The volatility ratio for the week is 6.48%, and the volatility levels for the last 30 days are 14.44% for Medicus Pharma Ltd (MDCX). The simple moving average for the last 20 days is -43.68% for MDCX stock, with a simple moving average of -23.72% for the last 200 days.
MDCX Trading at -38.02% from the 50-Day Moving Average
After a stumble in the market that brought MDCX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.13% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at MDCX starting from VELOCITY FUND PARTNERS, LP, who sale 75,000 shares at the price of $7.72 back on May 20 ’25. After this action, VELOCITY FUND PARTNERS, LP now owns 3,248,741 shares of Medicus Pharma Ltd, valued at $578,940 using the latest closing price.
VELOCITY FUND PARTNERS, LP, the Major Shareholders of Medicus Pharma Ltd, proposed sale 118,000 shares at $195.49 during a trade that took place back on May 20 ’25, which means that VELOCITY FUND PARTNERS, LP is holding shares at $23,067,500 based on the most recent closing price.
Stock Fundamentals for MDCX
The total capital return value is set at -6.26. Equity return is now at value -1882.04, with -435.53 for asset returns.
Based on Medicus Pharma Ltd (MDCX), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -44.15. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -16.26.
Currently, EBITDA for the company is -10.62 million with net debt to EBITDA at 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.
Conclusion
To wrap up, the performance of Medicus Pharma Ltd (MDCX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
